<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850144</url>
  </required_header>
  <id_info>
    <org_study_id>3122005</org_study_id>
    <nct_id>NCT04850144</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler®</brief_title>
  <acronym>TESSA</acronym>
  <official_title>Comparison of Tiotropium Pharmacokinetics After Inhalation From Tiotropium Easyhaler® Product Variants and After Spiriva® Capsules Administered Via HandiHaler®; Study in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Absorption of inhaled tiotropium is compared between five Tiotropium Easyhaler product&#xD;
      variants and Spiriva capsules inhaled via HandiHaler without charcoal. Absorption of&#xD;
      tiotropium is compared between one Easyhaler product variant administered with and without&#xD;
      charcoal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Actual">October 4, 2021</completion_date>
  <primary_completion_date type="Actual">October 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study is a 2-part 4-period crossover study where the study subjects participate either in part 1 (20 subjects) or in part 2 (20 subjects). Parts can run in sequence or parallel. All study subjects receive single dose of Tiotropium Easyhaler on 3 periods and Spiriva HandiHaler on 1 period.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Bioanalytical laboratory will be blinded with regard to the sequence of the product administration.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak tiotropium concentration in plasma (Cmax)</measure>
    <time_frame>between 0-72 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to 30 minutes (AUC30 minutes)</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to 72 hours (AUC72 hours)</measure>
    <time_frame>0-72 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach peak concentration in plasma (tmax)</measure>
    <time_frame>between 0-72 hours after dosing</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>througout the study, an average 9 weeks</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product variant D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product variant E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product variant F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product variant G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product variant H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva HandiHaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product variant F administered with oral activated charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Tiotropium Easyhaler 10 µg/dose Product variant D</description>
    <arm_group_label>Tiotropium Easyhaler Product variant D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Tiotropium Easyhaler 10 µg/dose Product variant E</description>
    <arm_group_label>Tiotropium Easyhaler Product variant E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Tiotropium Easyhaler 10 µg/dose Product variant F</description>
    <arm_group_label>Tiotropium Easyhaler Product variant F</arm_group_label>
    <arm_group_label>Tiotropium Easyhaler Product variant F administered with oral activated charcoal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Tiotropium Easyhaler 10 µg/dose Product variant G</description>
    <arm_group_label>Tiotropium Easyhaler Product variant G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Tiotropium Easyhaler 10 µg/dose Product variant H</description>
    <arm_group_label>Tiotropium Easyhaler Product variant H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Spiriva 18 µg/capsule inhaled via Handihaler</description>
    <arm_group_label>Spiriva HandiHaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Easyhaler with oral activated charcoal</intervention_name>
    <description>The charcoal suspension will be administered orally with Tiotropium Easyhaler 10 µg/dose Product variant F</description>
    <arm_group_label>Tiotropium Easyhaler Product variant F administered with oral activated charcoal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:&#xD;
&#xD;
          1. Healthy males and females&#xD;
&#xD;
          2. 18-60 years of age&#xD;
&#xD;
          3. Body mass index 19-30 kg/m2&#xD;
&#xD;
          4. Weight at least 50 kg&#xD;
&#xD;
          5. Written informed consent obtained&#xD;
&#xD;
        Main exclusion criteria:&#xD;
&#xD;
          1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,&#xD;
             gastrointestinal, pulmonary, metabolic, endocrine, neurological or psychiatric disease&#xD;
&#xD;
          2. Any condition requiring regular concomitant treatment&#xD;
&#xD;
          3. Any clinically significant abnormal laboratory value or physical finding that in the&#xD;
             opinion of the investigator could interfere with the interpretation of study results&#xD;
             or cause a health risk for the subject&#xD;
&#xD;
          4. Known hypersensitivity to tiotropium bromide, atropine or its derivatives or lactose&#xD;
&#xD;
          5. Pregnant or lactating females and females of childbearing potential not using&#xD;
             contraception of acceptable effectiveness&#xD;
&#xD;
          6. Blood donation or loss of significant amount of blood within 90 days prior to the&#xD;
             first study treatment administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orion Corporation Clinical Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit, Orion Corporation</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

